Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic

Bibliography

• TARSEY D: Neuroleptic-induced extrapyramidal reac-tions: classification, description and diagnosis. Clin. Neuropharmacol. (1983) 6\(Suppl. 1):S9–S26.
   Google Scholar
• KANE JM: Tardive dyskinesia: epidemiological and clinical presentation. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds.), Raven Press, New York (1995) 1485–1495.
   Google Scholar
• SALTZ BL, WOERNER MG, KANE JM et al.: Prospective study of tardive dyskinesia incidence in the elderly. JAMA (1991) 266(17):2402–2406.
   PubMed Web of Science ®Google Scholar
• KANE J, JESTE DV, BARNES TRE et al.: American Psychiat-ric Association Task Force report on tardive dyskinesia. American Psychiatric Press, Washington DC (1992).
   Google Scholar
• GRATZ SS, LEVINSON DF, SIMPSON GM: Neuroleptic ma-lignant syndrome. In: Adverse Effects of Psychotropic Drugs. Kane JM, Lieberman JA (Eds.), Guilford Press, New York (1992) 266–284.
   Google Scholar
• JANICAK PG, DAVIS JM, PRESKORN SH, AYD FJ, Jr.: Princi-ples and Practice of Psychopharmacology. Williams and Wilkins, Baltimore (1969).
   Google Scholar
• KLEIN DF, DAVIS JM: Diagnosis and Treatment of Psychiat-ric Disorders. Williams and Wilkins, Baltimore (1969).
   Google Scholar
• CASEY DE: Clozapine: neuroleptic-induced EPS and tar-dive dyskinesia. Psychopharmology (1989) 53:S47–S53.
   Google Scholar
• KANE JM, COOPER TB, SACHAR EJ, HALPERN FS, BAILINE S: Clozapine: plasma levels and prolactin response. Psy-chopharmacology(1981) 73:184–187.
   PubMed Web of Science ®Google Scholar
• KANE J, HONIGFELD G, SINGER J, MELTZER H: Clozazap-ine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromaz-ine/benztropine. Arch. Gen. Psychiatry (1988) 45:789–796.
   PubMed Web of Science ®Google Scholar
• CARPENTER WT, Jr., CONLEY RR, BUCHANAN RW, BREIER A, TAMMINGA CA: Patients response and resource man-agement: another view of clozapine treatment of schizophrenia. Am. J. PsychiaL (1995) 152:827–832.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: Clozapine: is another view valid? Am. J. PsychiaL (1995) 152:821–825.
   PubMed Web of Science ®Google Scholar
• ALVIR JM, LIEBERMAN JA, SAFFERMAN AZ, SCHLIMMER IL:Clozapine-induced agranulocytosis: incidence and risk factors in the United States. New Engl. J. Med. (1993) 329:162–167.
   PubMed Web of Science ®Google Scholar
• DEVINSKY O, PACIA SD: Seizures during clozapine ther-apy. J. Clin. PsychiaL (1994) 55 (Suppl. B):153–156.
   Google Scholar
• SANCHEZ C, ARNT J, DRAGSTED N et al.: Neurochemicaland in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev. Res. (1991) 22(3):239–250.
   Web of Science ®Google Scholar
• HYTTEL J, ARNT J, COSTALL B et al.: Pharmacologicalprofile of the atypical neuroleptic sertindole. Clin. Neu-ropharmacol. (1992) 15 (0 :267.
   Google Scholar
• HYTTEL J, NIELSEN JP, NOWAK G: The acute effect of sert-indole on brain 5-111‘2, Dy and ai receptors (ex vivo ra-dioreceptor binding studies). J. Neural Trans. (1992) 89 (1-2) :61–69.
   PubMed Web of Science ®Google Scholar
• SKARSFELDT T: Effect of repeated neuroleptic treatment on spontaneously active neurons in the VTA and SNC area in rats. Correlation to antipsychotic activity in the clinic? Schizophren. Res. (1992) 6(2):117.
   Web of Science ®Google Scholar
• FINK-JENSEN A, HANSEN L, KRISTENSEN P: Comparison of the effect of clozapine, risperidone, sertindole and haloperidol on interstitial DOPAC levels and c-fos ex-pression in limbic and non-limbic regions of the rat brain. Psychopharmacology (1994) 114:9.
   PubMedGoogle Scholar
• JACKSON DM, JOHANSSON C, LINDREN LM, BENGTSSONA: Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol. Biochem. Behav. (1994) 48(2):465–471.
   PubMed Web of Science ®Google Scholar
• SANGER DJ, PERRAULT G: Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J. Pharmacol Exp. Ther. (1995) 272(2)708–713.
   Google Scholar
• CASEY DE: Behavioural effects of sertindole, risperi-done, clozapine and haloperidol in cebus monkeys. Psychopharmacology (1996) 124:134–140.
   PubMed Web of Science ®Google Scholar
• GAO X-M, SAKAI K, TAMMINGA CA: Neuroleptic-induced oral dyskinesia in rats treated with olanzapine, sertin-dole and haloperidol. NeuroscL Abstr. (1996) 22:1087.
   Google Scholar
• VAN KAMMEN DP, MCEVOY JP, TARGAM SD, KARDATZKE D, SEBREE TB: A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psy-chopharmacology (1996) 124:168–175.
   PubMed Web of Science ®Google Scholar
• GRANNEMAN GR, WOZNIAK P, ERESHEFSKY L, SILBER C,MACK R: Population pharmacokinetics of sertindole during long-term treatment of patients with schizo-phrenia. (Submitted).
   Google Scholar
• FRIBERG HH, SKARSKFELDT T, PIERCE M et al.: Sertin-dole, a novel atypical neuroleptic drug candidate - safety and tolerance in normal human subjects. Schizophr. Res. (1992) 6 (2) :111–112.
   Web of Science ®Google Scholar
• OVERALL JE, GORHAM DR: Brief Psychiatric Ratings Scale Psychological Reports (1962) 10:799–812.
   Google Scholar
• KAY SR, FISZBEIN A, OPLER LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. (1987) 13:261–276.
   PubMed Web of Science ®Google Scholar
• ANDREASEN NC: Negative symptoms in schizophrenia: Definition and reliability. Arch. J. PsychiaL (1982) 39:784–788.
   PubMed Web of Science ®Google Scholar
• ECDEU Assessment Manual for Psychopharmacology: Publi-cation ADM 76–338. Guy W (Ed.), US Department of Health, Education and Welfare, Washington DC (1976) 219–222.
   Google Scholar
• MCEVOY J, BORISON R, SMALL J et al.: The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose-ranging study. Schizophren. Res. (1993) 9(2,3):244.
   Google Scholar
• POTKIN SG, TARGUM SD, ZBOROWSKI BSN, WOZINAK P, KASHKIN KB: Comparative safety and efficacy of sertin-dole and haloperidol in patients with schizophrenia. (Submitted).
   Google Scholar
• ZIMBROFF DL, KANE JM, TAMMINGA CA et al.: Controlled, dose-response of sertindole and haloperidol in the treatment of schizophrenia. Am. J. PsychiaL (1997) 1154:782–791.
   Google Scholar
• SWANN AC, MACK RJ, STASER JA, HOLGATE KL, SILBER CJ: An assessment of the long-term safety, efficacy, quality of life and relapse in sertindole versus haloperidol-treated stable schizophrenic patients [poster presenta-tion]. Institute on Psychiatric Services. Chicago, IL (18–22 Oc-tober 1996).
   Google Scholar
• KAPUR S, REMINGTON G, JONES C et al.: High levels of dopamine D2 receptor occupancy with low dose ha-loperidol treatment: a PET study. Am. J. PsychiaL (1996) 151:948–950.
   Google Scholar
• GARSON A: How to measure the QT interval - what is normal? Am. J. Cardiol. (1993) 72:14B–16B.
   Google Scholar
• BALDESSARINI RJ: Drugs and treatment of psychiatric disorders, psychosis and anxiety. In: The Pharmacologic Basis of Therapeutics (Ninth Edition). Hardman JG, Minbird LE, Molinoff PB, Ruddon RW, Gilman AG (Eds.), McGraw Hill, New York (1996) 399–430.
   Google Scholar